Palomar Holdings, Inc. (NASDAQ:PLMR - Get Free Report) COO Rodolphe Herve sold 1,207 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $135.35, for a total transaction of $163,367.45. Following the transaction, the chief operating officer directly owned 3,548 shares of the company's stock, valued at $480,221.80. This represents a 25.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Palomar Stock Down 0.3%
Shares of PLMR stock traded down $0.40 during trading on Tuesday, reaching $136.11. The company's stock had a trading volume of 171,135 shares, compared to its average volume of 270,371. The business has a fifty day moving average price of $124.76 and a 200-day moving average price of $123.54. The company has a quick ratio of 0.49, a current ratio of 0.49 and a debt-to-equity ratio of 0.31. The company has a market cap of $3.61 billion, a price-to-earnings ratio of 18.96 and a beta of 0.40. Palomar Holdings, Inc. has a one year low of $100.81 and a one year high of $147.62.
Palomar (NASDAQ:PLMR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $2.36 EPS for the quarter, topping the consensus estimate of $2.19 by $0.17. The business had revenue of $314.42 million during the quarter, compared to analysts' expectations of $621.52 million. Palomar had a net margin of 20.11% and a return on equity of 22.62%. Analysts anticipate that Palomar Holdings, Inc. will post 8.9 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on PLMR. Piper Sandler increased their price objective on shares of Palomar from $132.00 to $165.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 15th. Evercore set a $152.00 target price on Palomar in a report on Friday, July 10th. Zacks Research cut Palomar from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 15th. Weiss Ratings upgraded Palomar from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, June 18th. Finally, JPMorgan Chase & Co. upped their price objective on Palomar from $150.00 to $167.00 and gave the stock an "overweight" rating in a research note on Monday, July 20th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $162.50.
View Our Latest Report on PLMR
Institutional Investors Weigh In On Palomar
Institutional investors and hedge funds have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new position in Palomar during the fourth quarter worth approximately $32,000. Kestra Advisory Services LLC acquired a new stake in shares of Palomar in the fourth quarter valued at approximately $33,000. Rockefeller Capital Management L.P. lifted its position in shares of Palomar by 81.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company's stock valued at $40,000 after buying an additional 132 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Palomar by 638.3% during the 1st quarter. Parallel Advisors LLC now owns 443 shares of the company's stock worth $53,000 after acquiring an additional 383 shares during the period. Finally, Frazier Financial Advisors LLC bought a new position in shares of Palomar during the 4th quarter worth approximately $54,000. 90.25% of the stock is owned by institutional investors.
About Palomar
(
Get Free Report)
Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Palomar, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palomar wasn't on the list.
While Palomar currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.